Compare Dyne Therapeutics Inc. Common Stock (DYN) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs United States Natural Gas Fund — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while United States Natural Gas Fund trades at $11.17 (market cap $503.45M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 5.7× United States Natural Gas Fund's market cap, and United States Natural Gas Fund is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and United States Natural Gas Fund for 23 Days on average.
| DYN | UNG | |
|---|---|---|
Market Cap | $2.86B | $503.45M |
Volume | 3,341,579 | 27,352,527 |
Sector | Health | Commodities - Energy |
52-Week High | $26.78 | $16.90 |
52-Week Low | $14.60 | $9.63 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The fund shows strong net income of $65.15M for 2024 despite zero revenue, supported by $593.54M in cash. Recent news highlights natural gas market volatility, with record U.S. production and geopolitical tensions influencing prices.
Outlook: Bullish technicals and solid liquidity offer upside, but reliance on natural gas price swings and zero revenue pose risks. Investors should weigh energy market stability against the fund's cash position and income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
